Ultragenyx Pharmaceutical Inc. buy Barclays PLC
Start price
06.08.24
/
50%
€45.20
Target price
06.08.25
€74.24
Performance (%)
-48.67%
End price
07.08.25
€23.20
Summary
This prediction ended on 07.08.25 with a price of €23.20. The BUY prediction by Barclays_PLC for Ultragenyx Pharmaceutical Inc. performed very badly with a performance of -48.67%. Barclays_PLC has a follow-up prediction for Ultragenyx Pharmaceutical Inc. where he still thinks Ultragenyx Pharmaceutical Inc. is a Buy. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -3.313% | -3.313% | -34.519% |
| iShares Core DAX® | 0.411% | 8.821% | 12.264% |
| iShares Nasdaq 100 | 3.678% | 10.820% | 44.017% |
| iShares Nikkei 225® | 2.701% | 15.247% | 48.041% |
| iShares S&P 500 | 2.445% | 7.933% | 32.998% |
Comments by Barclays_PLC for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target lowered by analysts at Barclays PLC from $83.00 to $81.00. They now have an "overweight" rating on the stock.
Ratings data for RARE provided by MarketBeat
In the thread Trading Ultragenyx Pharmaceutical Inc.
Die von Barclays_PLC gewählte maximale Laufzeit wurde überschritten
Current prediction by Barclays_PLC for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€28.40
24.11.25
24.11.25
€43.44
24.11.26
24.11.26
-25.95%
09:46
09:46
